Navigation Links
Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation
Date:11/8/2010

BEDMINSTER, N.J., Nov. 8, 2010 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova™, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza®, the leading prescription Omega-3.  Epanova is an Omega-3 fatty acid compound containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The primary objective of the four-week study, called ECLIPSE (Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation), is to compare the bioavailability of EPA from Epanova and Lovaza in either a low or high fat diet setting.  

The study will include 50 subjects.  In the four cross-over periods, all subjects will be given a single 4-gram dose of either Epanova or Lovaza with low and high fat meals.  Data is expected from this study in the first quarter of 2011.

"Several studies have compared the absorption of Omega-3 fatty acids in the ethyl ester and free fatty acid forms and found that the free fatty acid form has up to four times greater bioavailability. Given that Epanova is a free fatty acid form of EPA and DHA, whereas Lovaza is an ethyl ester EPA and DHA product, Epanova may offer distinct advantages in the marketplace," said Dr. Michael Davidson, Chief Medical Officer of Omthera Pharmaceuticals.  "Further, free fatty acid Omega-3s are well absorbed when given with a low fat meal and may therefore have clinical relevance in patients with hypertriglyceridemia who should be maintained on a low fat diet."

About Epanova™Epanova is a patent protected, novel, ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  Omthera has deve
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
2. Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
7. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
8. NanoSmartâ„¢ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
10. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
11. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... DIEGO , Feb. 27, 2015  Pfenex Inc. ... the development of biosimilar therapeutics, today announced that it ... Francisco Marriott Marquis on March 2 nd at ... participate on a panel discussing the current state of ... of Biosimilars . For more information ...
(Date:2/26/2015)... -- S&P Capital IQ (MHFI) announced today that it ... Therapeutics Holdings Inc . MabVax Therapeutics ... focused on the development of vaccine and antibody-based therapies ... cancer. MabVax has discovered a pipeline of human monoclonal ... by patients who have been immunized against targeted cancers. ...
(Date:2/26/2015)... 26, 2015   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and Chief Executive Officer of Regulus, will present a ... Annual Healthcare Conference on Wednesday, March 4, 2015 ... at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the ... hair rejuvenation, has announced that it has selected ... investor relations and strategic communications. ... diversification strategies – and we need to communicate ... Ali Kharazmi CEO of NuGene when announcing this ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... a $500,000 start-up grant for the recently announced ... classified, defense-related projects. , ,The consortium, led ... include the UW System, the Medical College of ... Milwaukee School of Engineering. , ,The consortium will ...
... Inc., a Wisconsin company specializing in functional Magnetic ... nomination for the 2005 edition of the Minnies, ... for radiologists and related professionals in medical imaging. ... in 12 categories. AuntMinnie.com members voted Neurognostics one ...
... one of a two part article. The next installment covering ... week. , , You or your company may ... with patent matters. However, there is a growing group of entities ... of revenue. As a consequence, more and more businesses have to ...
Cached Biology Technology:Wisconsin consortium aims for defense business 2Patent enforcement: What you don't know might hurt you 2Patent enforcement: What you don't know might hurt you 3Patent enforcement: What you don't know might hurt you 4
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... An electronic device designed to "zap" away migraine pain before ... millions of people who suffer from the debilitating disease. ... appears to be effective in eliminating the headache when administered ... led by the Ohio State University Medical Center neurology investigators, ...
... most powerful tools of biomedical science, University of Texas ... dramatic success in the battle against colorectal cancer. , ... known as "small interfering RNAs" to block the spread ... Small interfering RNAs (siRNAs), first described in 2001, are ...
... that causes African sleeping sickness, scientists at Johns Hopkins have ... component of fat and the outer layer of all cells. ... parasite and could lead to a target for designing new ... and kills 50,000 a year worldwide. , Results of the ...
Cached Biology News:Device effective in zapping the pain out of migraines 2RNA interference stops colon cancer spread in mice 2African parasite makes component of fat differently from all other organisms 2African parasite makes component of fat differently from all other organisms 3
...
... immunostaining ,This solution has effect on enhancing ... clearer signal than the one obtained by ... of secondary antibody used and exposure time ... have images with high S/N ratio and ...
... normal tissues this enzyme exists predominantly as ... uric acid, a critical plasma antioxidant. ... the oxygen radical producing XO by oxidation ... limited proteolytic cleavage of the amino-terminus. ...
... the gap between the 500 l and ... the speed of the classic Vivaspin products ... for superior recoveries from very dilute solutions. ... Cellulose Triacetate membranes, Vivaspin 2 offers the ...
Biology Products: